Dogwood Therapeutics (NASDAQ: DWTX) has announced the appointment of Iain Dukes, PhD, as chair of the company’s scientific advisory board (SAB).
Dr. Dukes is a veteran biopharma industry executive and partner with investment firm OrbiMed.
In a statement, Greg Duncan, CEO of Dogwood, commented, “Iain is widely recognized throughout the biopharma industry as a successful scientist, investor and business leader, and we are delighted to welcome him as chair of our newly formed SAB. Dr. Dukes has deep experience in the field of ion channel therapeutics development, and this experience is directly relevant to our ongoing development of Halneuron, a NaV 1.7 sodium channel inhibitor. We look forward to his guidance and expertise as we further expand our SAB and advance our pipeline of novel therapeutics for pain and neuropathy.”
